The FDA expanded Furoscix use to certain pediatric patients. ・MannKind received five new U.S. patents supporting its ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...

This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing ...

The company announced initial meal challenge data from INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin (plus basal) versus the current standard of care. “One of the challenges of inhaled ...

Shares of MannKind (NASDAQ:MNKD) were up 10% in midday trading Friday after Wells Fargo initiated coverage of the stock with an overweight rating and a price target of $9. The investment bank said in ...

MannKind (NASDAQ:MNKD) will reduce its outstanding debt by $194M following exchange of convertible notes for stock and cash. The company entered into separate, privately negotiated exchange agreements ...

The reason for the stock's jump wasn't hard to tease out. MannKind, which concentrates on developing treatments for endocrine and lung disorders, published its second quarter results that day. The ...

・Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand. ・Revenue from the V-Go insulin delivery patch, however, slipped 19% to ...

MannKind (MNKD) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago. These figures are ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: MannKind ...